MedTrace Logo

A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

NCT02999295 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2019-08-21

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the safety and efficacy of the combination therapy of ramucirumab and nivolumab in participants with advanced or recurrent unresectable gastric or GEJ cancer.

Conditions

Interventions

BIOLOGICAL

Ramucirumab

Ramucirumab (8 mg/kg) is administered.

BIOLOGICAL

Nivolumab

Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered.

Sponsors & Collaborators

  • Ono Pharmaceutical Co. Ltd

    collaborator INDUSTRY

  • Fiverings Co., Ltd.

    collaborator OTHER

  • National Cancer Center, Japan

    lead OTHER_GOV

Principal Investigators

  • Ken Kato, M.D. / Ph.D. · Department of Gastrointestinal Medical Oncology, National cancer center hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2017-11-30
Completion
2019-08-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02999295 on ClinicalTrials.gov